Guided Therapeutics (GTHP) Short-Term Debt issuances (2020 - 2022)

Guided Therapeutics' Short-Term Debt issuances history spans 3 years, with the latest figure at -$90000.0 for Q1 2022.

  • On a quarterly basis, Short-Term Debt issuances rose 83.84% to -$90000.0 in Q1 2022 year-over-year; TTM through Mar 2022 was -$842000.0, a N/A change, with the full-year FY2021 number at -$1.5 million, down 33.33% from a year prior.
  • Short-Term Debt issuances hit -$90000.0 in Q1 2022 for Guided Therapeutics, down from -$53000.0 in the prior quarter.
  • Over the last five years, Short-Term Debt issuances for GTHP hit a ceiling of -$53000.0 in Q4 2021 and a floor of -$557000.0 in Q1 2021.
  • Historically, Short-Term Debt issuances has averaged -$210500.0 across 3 years, with a median of -$116000.0 in 2020.
  • Biggest five-year swings in Short-Term Debt issuances: skyrocketed 62.68% in 2021 and later skyrocketed 83.84% in 2022.
  • Tracing GTHP's Short-Term Debt issuances over 3 years: stood at -$142000.0 in 2020, then skyrocketed by 62.68% to -$53000.0 in 2021, then crashed by 69.81% to -$90000.0 in 2022.
  • Business Quant data shows Short-Term Debt issuances for GTHP at -$90000.0 in Q1 2022, -$53000.0 in Q4 2021, and -$557000.0 in Q1 2021.